Sunnova Energy International (NASDAQ:NOVA) Reaches New 52-Week High Following Analyst …

Finally, Kohlberg Kravis Roberts & Co. L.P. bought a new position in Sunnova Energy International in the 3rd quarter worth approximately $6,289,000.

Sunnova Energy International logoSunnova Energy International Inc. (NASDAQ:NOVA) shares hit a new 52-week high during trading on Wednesday after KeyCorp raised their price target on the stock from $14.00 to $18.00. KeyCorp currently has an overweight rating on the stock. Sunnova Energy International traded as high as $18.27 and last traded at $17.99, with a volume of 339383 shares. The stock had previously closed at $16.24.

A number of other research analysts have also recently issued reports on the stock. LADENBURG THALM/SH SH initiated coverage on shares of Sunnova Energy International in a research note on Monday, January 6th. They issued a “buy” rating and a $15.00 target price for the company. Zacks Investment Research cut shares of Sunnova Energy International from a “hold” rating to a “sell” rating in a research note on Thursday, January 9th. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $15.33.

A number of hedge funds have recently bought and sold shares of the stock. Newlight Partners LP bought a new position in Sunnova Energy International in the 4th quarter worth approximately $107,528,000. Handelsbanken Fonder AB raised its position in Sunnova Energy International by 16.6% in the 4th quarter. Handelsbanken Fonder AB now owns 3,044,164 shares of the company’s stock worth $33,973,000 after purchasing an additional 432,393 shares during the last quarter. FMR LLC raised its position in Sunnova Energy International by 84.4% in the 4th quarter. FMR LLC now owns 2,052,500 shares of the company’s stock worth $22,906,000 after purchasing an additional 939,700 shares during the last quarter. Jefferies Group LLC raised its position in Sunnova Energy International by 31.7% in the 4th quarter. Jefferies Group LLC now owns 643,716 shares of the company’s stock worth $7,184,000 after purchasing an additional 155,120 shares during the last quarter. Finally, Kohlberg Kravis Roberts & Co. L.P. bought a new position in Sunnova Energy International in the 3rd quarter worth approximately $6,289,000.

The firm’s 50-day moving average is $13.23 and its two-hundred day moving average is $11.23.

Sunnova Energy International Company Profile (NASDAQ:NOVA)

Sunnova Energy International Inc focuses on operating as a holding company for Sunnova Energy Corporation that provides residential solar and energy storage services in the United States, Puerto Rico, and the Northern Mariana Islands. Its services include operations and maintenance, monitoring, repairs and replacements, equipment upgrades, onsite power optimization, and diagnostics.

Recommended Story: Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Sunnova Energy International Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sunnova Energy International and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Today Raymond James Financial Inc (NYSE:RJF) Reported Decrease in Shorted Shares

Toronto Dominion Bancorp holds 0% or 74,364 shares. Bridgewater Associates Limited Partnership holds 35,798 shares. Comerica Savings Bank has …

Raymond James Financial, Inc. (NYSE:RJF) Logo

Investors sentiment increased to 0.97 in Q2 2019. Its up 0.03, from 0.94 in 2019Q1. It improved, as 30 investors sold Raymond James Financial, Inc. shares while 140 reduced holdings. 51 funds opened positions while 114 raised stakes. 92.55 million shares or 2.04% less from 94.48 million shares in 2019Q1 were reported.

Qs reported 1,200 shares stake. Regions Corporation invested in 0.02% or 20,472 shares. Quantbot Technology Lp invested in 0.01% or 1,453 shares. Retirement Sys Of Alabama stated it has 0.02% in Raymond James Financial, Inc. (NYSE:RJF). Vanguard Group invested in 13.79 million shares or 0.04% of the stock. Arizona-based Tci Wealth has invested 0% in Raymond James Financial, Inc. (NYSE:RJF). Financial Bank Of New York Mellon holds 0.04% or 1.79 million shares. First Trust Ltd Partnership holds 0.12% in Raymond James Financial, Inc. (NYSE:RJF) or 772,906 shares. Zebra Capital Mgmt Lc holds 0.13% of its portfolio in Raymond James Financial, Inc. (NYSE:RJF) for 3,011 shares. Group One Trading Limited Partnership holds 2,000 shares or 0% of its portfolio. Meeder Asset Inc invested in 102 shares or 0% of the stock. Highland Cap Management Lp has 3,835 shares for 0.02% of their portfolio. Toronto Dominion Bancorp holds 0% or 74,364 shares. Bridgewater Associates Limited Partnership holds 35,798 shares. Comerica Savings Bank has 0.03% invested in Raymond James Financial, Inc. (NYSE:RJF) for 41,070 shares.

The stock of Raymond James Financial Inc (NYSE:RJF) registered a decrease of 15.45% in short interest. RJF’s total short interest was 1.76 million shares in September as published by FINRA. Its down 15.45% from 2.08 million shares, reported previously. With 928,200 shares average volume, it will take short sellers 2 days to cover their RJF’s short positions. The short interest to Raymond James Financial Inc’s float is 1.4%.

The stock increased 0.81% or $0.7 during the last trading session, reaching $87.11. About 998,657 shares traded or 4.85% up from the average. Raymond James Financial, Inc. (NYSE:RJF) has declined 11.35% since September 15, 2018 and is downtrending. It has underperformed by 11.35% the S&P500.

Raymond James Financial, Inc., a financial holding company, through its subsidiaries, engages in the underwriting, distribution, trading, and brokerage of equity and debt securities, and the sale of mutual funds and other investment products in the United States, Canada, Europe, and internationally. The company has market cap of $12.10 billion. The firm operates through Private Client Group, Capital Markets, Asset Management, RJ Bank, and Other divisions. It has a 12.35 P/E ratio. The Private Client Group segment provides securities brokerage services, including the sale of equities, mutual funds, fixed income products, and insurance products to their individual clients; and borrowing and lending of securities to and from other broker-dealers, financial institutions, and other counterparties.

Raymond James Financial, Inc. (NYSE:RJF) Ratings Coverage

Among 2 analysts covering Raymond James Financial (NYSE:RJF), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Raymond James Financial has $94 highest and $9200 lowest target. $93’s average target is 6.76% above currents $87.11 stock price. Raymond James Financial had 7 analyst reports since March 23, 2019 according to SRatingsIntel. The company was maintained on Friday, April 5 by Wells Fargo. The firm has “Neutral” rating given on Monday, April 15 by Citigroup.

More notable recent Raymond James Financial, Inc. (NYSE:RJF) news were published by: Seekingalpha.com which released: “Raymond James Financial: Positioned To Thrive In The Next Crisis – Seeking Alpha” on July 09, 2019, also Seekingalpha.com with their article: “Raymond James July client AUM rises to record $831.1B – Seeking Alpha” published on August 21, 2019, Bizjournals.com published: “Raymond James launches $750M stock buyback – Tampa Bay Business Journal” on August 19, 2019. More interesting news about Raymond James Financial, Inc. (NYSE:RJF) were released by: Seekingalpha.com and their article: “Raymond James Financial Q3 2019 Earnings Preview – Seeking Alpha” published on July 23, 2019 as well as Seekingalpha.com‘s news article titled: “Key Risks Weighing Down Raymond James Financial, Inc. – Seeking Alpha” with publication date: June 19, 2019.

Raymond James Financial, Inc. (NYSE:RJF) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Youngevity International Inc (NASDAQ:YGYI) Short Interest Update

Vanguard Group Inc. grew its holdings in shares of Youngevity International by 18.5% during the 2nd quarter. Vanguard Group Inc. now owns 474,118 …

Youngevity International logoYoungevity International Inc (NASDAQ:YGYI) was the target of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 1,265,300 shares, a growth of 8.7% from the July 31st total of 1,163,500 shares. Approximately 8.9% of the company’s shares are short sold. Based on an average daily volume of 90,200 shares, the short-interest ratio is presently 14.0 days.

Separately, ValuEngine lowered Youngevity International from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st.

YGYI opened at $4.87 on Friday. The business has a 50 day simple moving average of $4.56 and a two-hundred day simple moving average of $5.56. The company has a quick ratio of 0.82, a current ratio of 1.23 and a debt-to-equity ratio of 0.50. Youngevity International has a one year low of $3.77 and a one year high of $16.25.

Youngevity International (NASDAQ:YGYI) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.02) EPS for the quarter. The business had revenue of $53.69 million for the quarter. Youngevity International had a negative net margin of 15.91% and a negative return on equity of 90.25%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in shares of Youngevity International by 2,064.8% during the 2nd quarter. BlackRock Inc. now owns 514,737 shares of the company’s stock worth $2,934,000 after acquiring an additional 490,959 shares during the period. 1492 Capital Management LLC grew its holdings in shares of Youngevity International by 347.8% during the 2nd quarter. 1492 Capital Management LLC now owns 107,313 shares of the company’s stock worth $612,000 after acquiring an additional 83,348 shares during the period. Vanguard Group Inc. grew its holdings in shares of Youngevity International by 18.5% during the 2nd quarter. Vanguard Group Inc. now owns 474,118 shares of the company’s stock worth $2,702,000 after acquiring an additional 74,183 shares during the period. Granite Investment Partners LLC grew its holdings in shares of Youngevity International by 87.7% during the 1st quarter. Granite Investment Partners LLC now owns 108,433 shares of the company’s stock worth $618,000 after acquiring an additional 50,679 shares during the period. Finally, Laurion Capital Management LP grew its holdings in shares of Youngevity International by 203.8% during the 1st quarter. Laurion Capital Management LP now owns 47,166 shares of the company’s stock worth $269,000 after acquiring an additional 31,643 shares during the period. 6.94% of the stock is owned by institutional investors and hedge funds.

Youngevity International Company Profile

Youngevity International, Inc develops and distributes health and nutrition related products and services through independent direct selling network in the United States and internationally. It operates in two segments, Direct Selling and Commercial Coffee. The company offers approximately 5,500 products, including nutritional, vitamin, mineral, herbal, liquid, and dietary supplements; apparel; fashion and jewelry accessories; digital products; and packaged foods.

Featured Story: Day Trading

Receive News & Ratings for Youngevity International Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Youngevity International and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Ingevity Corp (NYSE:NGVT) Holdings Boosted by Allianz Asset Management GmbH

Finally, WINTON GROUP Ltd increased its position in Ingevity by 2.0% during the 2nd quarter. WINTON GROUP Ltd now owns 8,532 shares of the …

Ingevity logoAllianz Asset Management GmbH grew its position in Ingevity Corp (NYSE:NGVT) by 5.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 254,361 shares of the company’s stock after buying an additional 13,223 shares during the quarter. Allianz Asset Management GmbH owned 0.61% of Ingevity worth $26,751,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Ingevity by 4.8% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 2,750 shares of the company’s stock valued at $290,000 after purchasing an additional 125 shares during the last quarter. Advisory Services Network LLC increased its position in Ingevity by 54.3% during the 2nd quarter. Advisory Services Network LLC now owns 355 shares of the company’s stock worth $37,000 after purchasing an additional 125 shares during the period. ETF Managers Group LLC increased its position in Ingevity by 8.3% during the 1st quarter. ETF Managers Group LLC now owns 1,941 shares of the company’s stock worth $205,000 after purchasing an additional 148 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in Ingevity by 7.2% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,382 shares of the company’s stock worth $252,000 after purchasing an additional 161 shares during the period. Finally, WINTON GROUP Ltd increased its position in Ingevity by 2.0% during the 2nd quarter. WINTON GROUP Ltd now owns 8,532 shares of the company’s stock worth $897,000 after purchasing an additional 164 shares during the period. 93.44% of the stock is owned by institutional investors and hedge funds.

Shares of NGVT traded up $0.93 during trading hours on Friday, hitting $91.02. The stock had a trading volume of 374,331 shares, compared to its average volume of 334,062. Ingevity Corp has a 12-month low of $72.59 and a 12-month high of $120.41. The firm has a market cap of $3.74 billion, a P/E ratio of 22.04, a P/E/G ratio of 1.82 and a beta of 2.09. The company has a debt-to-equity ratio of 3.51, a quick ratio of 1.25 and a current ratio of 2.28. The company’s fifty day simple moving average is $83.28 and its 200 day simple moving average is $97.89.

Ingevity (NYSE:NGVT) last announced its earnings results on Wednesday, July 24th. The company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.01. The company had revenue of $352.80 million during the quarter, compared to the consensus estimate of $362.06 million. Ingevity had a return on equity of 54.67% and a net margin of 14.03%. The company’s revenue was up 14.3% on a year-over-year basis. During the same period last year, the firm earned $1.12 earnings per share. As a group, sell-side analysts predict that Ingevity Corp will post 4.91 earnings per share for the current fiscal year.

A number of equities research analysts recently weighed in on NGVT shares. Jefferies Financial Group cut Ingevity from a “buy” rating to a “hold” rating and lowered their price target for the stock from $129.00 to $107.00 in a report on Friday, July 19th. BMO Capital Markets started coverage on Ingevity in a report on Thursday, July 18th. They issued an “outperform” rating and a $101.29 price target on the stock. ValuEngine cut Ingevity from a “hold” rating to a “sell” rating in a report on Tuesday, August 6th. Loop Capital raised Ingevity from a “hold” rating to a “buy” rating in a research note on Thursday, September 5th. Finally, Berenberg Bank raised Ingevity from a “hold” rating to a “buy” rating and reduced their target price for the company from $120.00 to $110.00 in a research note on Tuesday, May 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $108.61.

Ingevity Profile

Ingevity Corporation manufactures and sells specialty chemicals and carbon materials in the United States and internationally. The company operates through two segments, Performance Materials and Performance Chemicals. The Performance Materials segment engineers, manufactures, and sells hardwood-based and chemically activated carbon products primarily for use in gasoline vapor emission control systems in cars, trucks, motorcycles, and boats.

Featured Story: Leveraged Buyout (LBO) Explained

Institutional Ownership by Quarter for Ingevity (NYSE:NGVT)

Receive News & Ratings for Ingevity Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ingevity and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Achieve Life Sciences Inc (NASDAQ:ACHV) Short Interest Up 8.3% in August

Finally, Vanguard Group Inc. boosted its holdings in Achieve Life Sciences by 152.2% during the second quarter. Vanguard Group Inc. now owns …

Achieve Life Sciences logoAchieve Life Sciences Inc (NASDAQ:ACHV) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 391,200 shares, a growth of 8.3% from the July 31st total of 361,300 shares. Based on an average trading volume of 189,500 shares, the days-to-cover ratio is currently 2.1 days. Approximately 6.0% of the shares of the stock are short sold.

A number of research firms recently commented on ACHV. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $20.00 price objective on shares of Achieve Life Sciences in a research note on Friday, August 9th. Maxim Group set a $6.00 price objective on shares of Achieve Life Sciences and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, ValuEngine upgraded shares of Achieve Life Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.

Shares of NASDAQ:ACHV opened at $2.25 on Friday. The stock has a market capitalization of $18.23 million, a price-to-earnings ratio of -0.62 and a beta of 1.96. Achieve Life Sciences has a 1-year low of $1.04 and a 1-year high of $5.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.62 and a current ratio of 3.62. The company has a 50 day moving average price of $1.94 and a 200 day moving average price of $2.80.

Achieve Life Sciences (NASDAQ:ACHV) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.17). On average, sell-side analysts expect that Achieve Life Sciences will post -1.6 EPS for the current fiscal year.

A number of large investors have recently modified their holdings of the stock. Jane Street Group LLC bought a new stake in Achieve Life Sciences during the second quarter worth approximately $32,000. Renaissance Technologies LLC boosted its holdings in Achieve Life Sciences by 12.5% during the second quarter. Renaissance Technologies LLC now owns 321,268 shares of the biopharmaceutical company’s stock worth $620,000 after buying an additional 35,607 shares in the last quarter. Searle & CO. boosted its holdings in Achieve Life Sciences by 80.4% during the second quarter. Searle & CO. now owns 132,592 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 59,092 shares in the last quarter. Sio Capital Management LLC boosted its holdings in Achieve Life Sciences by 24.4% during the second quarter. Sio Capital Management LLC now owns 524,413 shares of the biopharmaceutical company’s stock worth $1,012,000 after buying an additional 102,934 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Achieve Life Sciences by 152.2% during the second quarter. Vanguard Group Inc. now owns 274,519 shares of the biopharmaceutical company’s stock worth $530,000 after buying an additional 165,667 shares in the last quarter. Hedge funds and other institutional investors own 18.63% of the company’s stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.

See Also: FAANG Stocks

Receive News & Ratings for Achieve Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Achieve Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts